Safety and Efficacy of Vildagliptin Versus NPH Insulin add-on to Glimepiride in Type 2 Diabetes Mellitus Patients.

Exclusion Criteria

• •Patients who are taking any other anti-diabetes drug (oral or injection) other than an SU component in the preceding 12 weeks.
• •Acute metabolic conditions such a ketoacidosis, lactic acidosis or hyperosmolar state within the past 6 month
• •Patients taking sulfonylurea for longer than 5 years
• •History of hypersensitivity to any of the study drugs or to drugs with similar chemical structures
• •pregnancy